美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Lakewood-Amedex Biotherapeutics (Direct Listing)

2.17

+0.05002.36%

盤後：2.13-0.0416-1.92%19:30 EDT

成交量：9.80萬

成交額：20.71萬

市值：514.22萬

市盈率：-0.21

高：2.17

開：2.17

低：2.07

收：2.12

52周最高：98.20

52周最低：1.66

股本：236.97萬

流通股本：141.56萬

量比：0.08

換手率：6.93%

股息：- -

股息率：- -

每股收益(TTM):-10.2000

每股收益(LYR):-8.3987

淨資產收益率：-402.84%

總資產收益率：-139.40%

市淨率：1.19

市盈率(LYR):-0.26

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

Lakewood-Amedex Biotherapeutics 完成感染性糖尿病足潰瘍二期a階段試驗最終籌備

Lakewood-Amedex Biotherapeutics - Nu-3在臨床前研究中展現良好耐受性，高劑量下系統暴露量低

Lakewood-Amedex Biotherapeutics公布臨床前安全性數據，支持Nu-3凝膠即將開展的2a期試驗劑量選擇

Lakewood-Amedex Biotherapeutics 準備推進 Nu-3 針對感染性糖尿病足潰瘍的二期臨床開發

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/LABT"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABT\",,,,,undefined,":{"symbol":"LABT","market":"US","secType":"STK","nameCN":"Lakewood-Amedex Biotherapeutics (Direct Listing)","latestPrice":2.17,"timestamp":1789502400000,"preClose":2.12,"halted":0,"volume":98031,"hourTrading":{"tag":"盘后","latestPrice":2.1284,"preClose":2.17,"latestTime":"19:30 EDT","volume":2868,"amount":6019.4234,"timestamp":1789515005748,"change":-0.0416,"changeRate":-0.019171,"amplitude":0.046083},"delay":0,"changeRate":0.023584905660377273,"floatShares":1415552,"shares":2369700,"eps":-10.199959,"marketStatus":"已收盤","change":0.05,"latestTime":"09-15 16:00:00 EDT","open":2.17,"high":2.17,"low":2.07,"amount":207094.3891338,"amplitude":0.04717,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-10.199959,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789545600000},"marketStatusCode":5,"adr":0,"listingDate":1776916800000,"exchange":"NASDAQ","adjPreClose":2.12,"preHourTrading":{"tag":"盘前","latestPrice":2.09,"preClose":2.12,"latestTime":"09:19 EDT","volume":3813,"amount":8052.987365999999,"timestamp":1789478364636,"change":-0.03,"changeRate":-0.014151,"amplitude":0.051887},"postHourTrading":{"tag":"盘后","latestPrice":2.1284,"preClose":2.17,"latestTime":"19:30 EDT","volume":2868,"amount":6019.4234,"timestamp":1789515005748,"change":-0.0416,"changeRate":-0.019171,"amplitude":0.046083},"volumeRatio":0.080709},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABT\",,,,,undefined,":{"symbol":"LABT","floatShares":1415552,"roa":"-139.40%","roe":"-402.84%","lyrEps":-8.39872,"volumeRatio":0.080709,"shares":2369700,"dividePrice":0,"high":2.17,"amplitude":0.04717,"preClose":2.12,"low":2.07,"week52Low":1.66,"pbRate":"1.19","week52High":98.2,"institutionHeld":0,"latestPrice":2.17,"eps":-10.199959,"divideRate":0,"volume":98031,"delay":0,"ttmEps":-10.199959,"open":2.17,"prevYearClose":80,"prevWeekClose":2.22,"prevMonthClose":2.5,"prevQuarterClose":3.14,"fiveDayClose":2.18,"twentyDayClose":2.16,"sixtyDayClose":3.861},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-06-22","symbol":"LABT","defaultRemindTime":1782135000000,"type":"split","dateTimestamp":1782100800000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LABT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LABT","date":"2026-09-14","current":-0.212746,"percent":0.831461,"low":-12.282138,"twenty":-2.729761,"median":-0.983162,"eighty":-0.729311,"high":-0.606341,"avg":-2.397029,"sd":3.1184,"marketCap":5260707},"quantilePoints":[{"date":"2026-05-08","current":-12.282138,"twenty":-12.192813,"median":-11.891342,"eighty":-11.604759,"marketCap":47257207},{"date":"2026-05-15","current":-7.294845,"twenty":-12.043939,"median":-11.649421,"eighty":-11.314454,"marketCap":28067917},{"date":"2026-05-22","current":-2.865088,"twenty":-11.850402,"median":-11.258627,"eighty":-3.412052,"marketCap":11023817},{"date":"2026-05-29","current":-2.716586,"twenty":-11.716415,"median":-6.438817,"eighty":-2.758568,"marketCap":10452435},{"date":"2026-06-05","current":-2.512255,"twenty":-11.604759,"median":-3.225364,"eighty":-2.559299,"marketCap":9666247},{"date":"2026-06-12","current":-2.69016,"twenty":-11.537766,"median":-2.813168,"eighty":-2.512255,"marketCap":10350760},{"date":"2026-06-18","current":-2.241304,"twenty":-11.42611,"median":-2.776507,"eighty":-2.512255,"marketCap":8623724},{"date":"2026-06-26","current":-1.276597,"twenty":-10.242559,"median":-2.72924,"eighty":-2.388094,"marketCap":4911883},{"date":"2026-07-02","current":-1.116845,"twenty":-7.294845,"median":-2.69016,"eighty":-1.477578,"marketCap":4725718},{"date":"2026-07-10","current":-0.893476,"twenty":-5.58279,"median":-2.580737,"eighty":-1.276597,"marketCap":3780575},{"date":"2026-07-17","current":-0.62611,"twenty":-3.536511,"median":-2.512255,"eighty":-1.062695,"marketCap":2649266},{"date":"2026-07-24","current":-1.03562,"twenty":-3.225364,"median":-2.41344,"eighty":-0.92732,"marketCap":4382030},{"date":"2026-07-31","current":-0.653185,"twenty":-2.937143,"median":-2.34533,"eighty":-0.879262,"marketCap":2763829},{"date":"2026-08-07","current":-0.754716,"twenty":-2.857942,"median":-1.477578,"eighty":-0.80819,"marketCap":3193440},{"date":"2026-08-14","current":-0.78856,"twenty":-2.830251,"median":-1.371504,"eighty":-0.793975,"marketCap":3336643},{"date":"2026-08-21","current":-0.706322,"twenty":-2.806803,"median":-1.276597,"eighty":-0.779084,"marketCap":5189616},{"date":"2026-08-28","current":-0.803079,"twenty":-2.760875,"median":-1.18284,"eighty":-0.754039,"marketCap":5900523},{"date":"2026-09-04","current":-0.612791,"twenty":-2.735567,"median":-1.116845,"eighty":-0.749426,"marketCap":4502407},{"date":"2026-09-11","current":-0.661169,"twenty":-2.730282,"median":-1.03562,"eighty":-0.735555,"marketCap":4857860},{"date":"2026-09-14","current":-0.715998,"twenty":-2.729761,"median":-0.983162,"eighty":-0.729311,"marketCap":5260707}],"updateTime":1789502415829},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABT\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1105205621","title":"Lakewood-Amedex Biotherapeutics 完成感染性糖尿病足潰瘍二期a階段試驗最終籌備","url":"https://stock-news.laohu8.com/highlight/detail?id=1105205621","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105205621?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 20:04","pubTimestamp":1784117062,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 已进入其针对感染性糖尿病足溃疡治疗的二期a阶段临床试验的最终准备阶段。公司正集中资源推进试验流程，标志着其核心疗法开发进入关键节点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146064134","title":"Lakewood-Amedex Biotherapeutics - Nu-3在臨床前研究中展現良好耐受性，高劑量下系統暴露量低","url":"https://stock-news.laohu8.com/highlight/detail?id=1146064134","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146064134?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 20:03","pubTimestamp":1784117015,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics（直接上市）宣布，其候选药物Nu-3在近期完成的临床前研究中取得了积极结果。数据显示，即使在较高剂量下，Nu-3也表现出良好的耐受性，且系统暴露水平维持在较低范围。这一发现为该药物的进一步开发提供了重要的安全性依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125245294","title":"Lakewood-Amedex Biotherapeutics公布臨床前安全性數據，支持Nu-3凝膠即將開展的2a期試驗劑量選擇","url":"https://stock-news.laohu8.com/highlight/detail?id=1125245294","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125245294?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 20:03","pubTimestamp":1784116990,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics公司宣布了其Nu-3凝胶的临床前安全性数据。这些关键数据为即将启动的2a期临床试验中的临床剂量选择提供了有力支持。研究结果表明，Nu-3凝胶在所测试的剂量范围内展现出良好的安全性特征，这为后续临床研究的顺利推进奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150730441","title":"Lakewood-Amedex Biotherapeutics 準備推進 Nu-3 針對感染性糖尿病足潰瘍的二期臨床開發","url":"https://stock-news.laohu8.com/highlight/detail?id=1150730441","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150730441?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 20:08","pubTimestamp":1783426135,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 正准备将其候选药物 Nu-3 推进至二期临床开发阶段，该药物旨在治疗感染性糖尿病足溃疡。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/LABT\",params:#limit:6,delay:false,,,undefined,":[]}}